Tuesday, May 29, 2018

SharedLabs IPO: Large Goodwill And Growing Through Acquisitions

With an astonishing revenue growth in 2016 and 2017, SharedLabs, Inc. (SHLB) is the next unicorn startup company that will sell shares in Wall Street. The company��s growth is sustained by innovative services in exciting sectors, such as artificial intelligence, blockchain, and the Internet of Things. Also, SHLB is growing as a result of ambitious acquisitions, such as iTech US, Inc., and SmartWorks, LLC.

Source: S-1

Business

Headquartered in Jacksonville, Florida, and founded in 2016, SharedLabs is an information technology services company. The company describes its services with the following words in the prospectus:

��We enable businesses and organizations to radically adapt as they harness our extensive experience with next-generation technologies like cloud hosting, big data analytics, artificial intelligence (��AI��), blockchain and the Internet of Things (��IoT��). Rather than offer a ��one size fits all�� approach, through strategy, consulting, design and implementation, we tailor our professional services to each client��s needs to provide customized IT solutions, allowing them to make the absolute most of our services.�� Source: S-1

SharedLabs consists of a group of five companies. The parent company, SharedLabs, Inc., is based in Delaware and controls four companies, which are headquartered in the United States and India. Have a look at the following figure and note that both iTech US, Inc. and SmartWorks, LLC, were acquired in 2017. The exponential growth of SharedLabs is best explained by the acquisition of these two entities:

Source: S-1

Before checking the financial figures, let me show what the company has achieved in only two years of existence. First of all, the group has five entities, but the number of office locations is more significant. I could count 13 office locations in the United States and India. Check out the following table:

Source: S-1

What��s more interesting is the number of employees, which, in my view, really shows the exponential growth of SharedLabs. In the last two years, the company has gone from no employees to, as of May 15, 2018, 550 employees all over the world. Doesn��t sound like an incredible story?

What��s the market opportunity?

According to the March 2017 report published by The Business Research Company (Source: S-1), the IT services industry in the United States is expected to grow at a compound annual growth rate (CAGR) of 5.1%. That said, the market is also very large. In 2020, its total value is expected to be $1,163 billion.

How is the growth in the industry sustained? That��s the most interesting. The report noted that advancements in AI and IoT are driving the demand in this market. Bearing in mind that SharedLabs is mainly focused on providing these services, I believe that the company should exhibit growth at a higher rate than the IT sector.

Financial Statements - The acquisitions, goodwill and intangibles

Taking into account that SHLB did not exist three years ago, the cash and asset generation is quite impressive. As of December 31, 2017, the total number of assets was equal to $34.18 million with $12.10 million in Goodwill and $9.01 million in intangible assets:

Source: S-1

You should have assumed that the Goodwill accumulated is from the acquisition of iTech US Inc., and its subsidiary SmartWorks, LLC, which we mentioned above:

Source

Are you interested in this disruptive acquisition? You need to know that iTech US, Inc. was founded in 2011 as shown by Bloomberg, and the business objective was similar to that of SharedLabs:

Source: Bloomberg

The company had large amount of employees, which considered the iTech a good place to work:

Source: LinkedIn


Source

The total value of the net assets acquired was equal to $16.885 million. They mainly consisted of $11.612 million in goodwill, trade names for $2.1 million, and $11.671 million in accounts receivable:

Source: S-1

Please note that the trade names and the customer relationships are the intangible assets that were shown in the balance sheet of SharedLabs. They have obviously suffered amortization in 2017 as shown in the following figure:

Source: S-1

How did the company pay for iTech? That��s another interesting feature. Like it happens in most acquisitions of emerging startups, iTech stockholders received a combination of cash, long-term debt, and warrants to purchase stock of SharedLabs. The following is the information that you need to know:

Source: S-1

Finally, I also need to mention that Exoi S, Inc. was also acquired in exchange of 149,067 shares of the company��s common stock. This amount of stock was said to be worth $711,285 in the prospectus:

Source: S-1

What��s my take? With three companies acquired in 2017, the company��s growth, undoubtedly, could not be explained without mentioning these transactions. Investors interested in this company need to really comprehend these acquisitions to assess the real value of each common stock of SharedLabs.

Taking into account the amount of money paid for Exoi S and iTech, we can use the following calculation to get an implied valuation of each share. SharedLabs acquired Exoi S and paid with 149,067 shares. The fair value of the stock issued was $711,285, which implies that each share is equal to $4.77. The company is selling shares at $5 in the IPO, which does not seem an absurd price given the amount paid for Exoi S.

That said, I need to raise the following concerns about the way SharedLabs is growing since it will affect the stock price. So far, the growth has been fueled by several transactions. The number of employees and business opportunities have exploded up, which has been welcomed. However, in the future, SharedLabs will not be able to acquire three companies per year. Thus, bear in mind that the growth will not be as remarkable in the near future. Additionally, if the acquisitions don��t really work out, the goodwill and the intangible assets will be diminished, which could lead to a reduction in the amount of net assets.

To sum up, be sure to revise the integration process and the goodwill in the balance sheet. The stock price will go up or down depending on these two features.

Financial statements - Liabilities and debt

As of December 31, 2017, SharedLabs exhibited $27.33 million in total liabilities, including approximately $4.6 million in debt as shown in the table below:

Source: S-1

The debt includes a business loan acquired to finance the acquisitions noted. This business loan was for total principal of $2 million plus interest at an annual rate of 20% for total interest of $0.8 million. While I don��t appreciate this term, I believe that if the company continues growing at the same pace, the interest expenses could be paid. The following is what you need to know:

Source: S-1

Revenues

Taking into account that the company did not exist in 2016, I believe that the revenue growth is astonishing. As of December 31, 2017, net revenue was equal to $36.22 million, and the gross profit accounted for approximately $5.1 million. While the net loss was equal to $1.79 million, I don��t believe that the investors will really care about it. This is an emerging company, and what really matters is the revenue and cash growth. The following is the income statement as provided in the prospectus:

Source: S-1

Lock-up agreements

Another very relevant feature that I will study closely is what insiders and directors do with their shares. If they commence to sell shares right after the IPO, which I expect to start in June, I will not be a buyer of this name.

Please note that the prospectus noted that the directors ��intend�� to enter into lock-up agreements that prohibit them from selling shares for a period of 12 months from the date of this offering:

Source: S-1

Conclusion

With an impressive and aggressive acquisition strategy, SharedLabs seems to be growing at a large pace, which, in my view, will seduce many investors. That said, I am not right now a buyer of the shares. I want to see how the company integrates the companies acquired before acquiring shares.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Monday, May 28, 2018

best stock buys

tags:SBLK,COR,CASY,PNTR,ANIP,NOG,

Cerus Corporation (CERS) is a $271 million market cap company focused on blood transfusion products. The company has viable products and anticipates it's increasing sales of platelet products is removing some previous sales ramp uncertainty. By expanding its supply agreement with the French National Blood Service, EFS, and the American Red Cross (plus increased funding from BARDA), Cerus is seeing positive signs for INTERCEPT Platelet systems demand. The company markets its systems in the U.S., Europe, and Middle East. With a global market of over $12 billion per year, the platelet replacement market is certainly substantial. The blood preparation market is expected to reach a whopping $64 billion by 2024. The company is also collaborating with Central California Blood Center to manufacture pathogen-reduced cryoprecipitate as a novel biologic, and is advancing its INTERCEPT red cell commercial development program including a planned FDA submission.

The company is overcoming obstacles faced by many players in the platelet manufacturing market space, including various shortages in production components and challenges in its commercial rollout. In contrast to the majority of blood components, which can be frozen, blood platelets are required to be stored at ambient temperature to be active and work properly. Unfortunately, these temperatures and conditions are ideal for the growth of bacteria. Incidence of bacterial contamination is believed to be significant, and is higher than the risk of viral contamination, which are also serious. Experts report infection can be the cause of medical complications and mortality, much of which may go unreported because of the presence of the patient��s underlying illness. Increasing geriatric population and rising prevalence of chronic diseases such as diabetes and glomerulonephritis will increase these markets (with a CAGR of 4.4%), as well as the severity risk for safe transfusion. Safety in blood transfusion is a primary concern for CERS, as they try to meet several unmet or under-met needs in this market space. The nucleic acid targeting mechanism of action of Cerus' INTERCEPT treatment inactivates pathogens (as reported at ISBT 2017) such as Hepatitis B and C, HIV, West Nile Virus and bacteria, as well as emerging hazards such as chikungunya, malaria and dengue.

best stock buys: Star Bulk Carriers Corp.(SBLK)

Advisors' Opinion:
  • [By Rich Smith]

    Now those new buy recommendations are rolling in. This morning, Stifel Nicolaus -- one of the best-rated analysts we have on Motley Fool CAPS -- announced a pair of such upgrades, urging investors to buy stock in Scorpio Bulkers (NYSE:SALT) and Star Bulk Carriers (NASDAQ:SBLK). Here's what you need to know.

best stock buys: CoreSite Realty Corporation(COR)

Advisors' Opinion:
  • [By ]

    CoreSite Realty (COR) : "The data centers have been hot, but the REITS have not. I'm a buyer of this stock, not a seller."

    Hi-Crush Partners (HCLP) : "This sector has gotten way too hot."

  • [By Jack Delaney]

    Take CoreSite Realty Corp. (NYSE: COR), for example. The stock price not only climbed 43.66% from 2017 to 2018, but it also pays its shareholders a dividend of $3.92 per share.

  • [By ]

    In the Lightning Round, Cramer was bullish on Align Technology (ALGN) , Berkshire Hathaway (BRK.A)   (BRK.B) , Criticare Systems Inc.  (CMD) , Thermo Fisher Scientific (TMO) , IAC Interactive (IAC) and CoreSite Realty (COR) .

best stock buys: Caseys General Stores, Inc.(CASY)

Advisors' Opinion:
  • [By Shane Hupp]

    Wall Street analysts forecast that Casey’s General Stores (NASDAQ:CASY) will announce sales of $2.14 billion for the current quarter, Zacks reports. Five analysts have issued estimates for Casey’s General Stores’ earnings. The highest sales estimate is $2.18 billion and the lowest is $2.12 billion. Casey’s General Stores reported sales of $1.85 billion in the same quarter last year, which would suggest a positive year over year growth rate of 15.7%. The business is scheduled to announce its next quarterly earnings report on Monday, June 4th.

best stock buys: Pointer Telocation Ltd.(PNTR)

Advisors' Opinion:
  • [By Lisa Levin]

    Pointer Telocation Ltd. (NASDAQ: PNTR) is projected to report quarterly earnings at $0.22 per share on revenue of $20.22 million.

    Tecogen Inc. (NASDAQ: TGEN) is estimated to report quarterly earnings at $0.01 per share on revenue of $9.43 million.

best stock buys: ANI Pharmaceuticals, Inc.(ANIP)

Advisors' Opinion:
  • [By Joseph Griffin]

    Canaccord Genuity set a $82.00 target price on ANI Pharmaceuticals (NASDAQ:ANIP) in a research report released on Tuesday morning. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

best stock buys: Northern Oil and Gas, Inc.(NOG)

Advisors' Opinion:
  • [By Ethan Ryder]

    Northern Oil and Gas Inc. (NYSEAMERICAN:NOG) has received a consensus recommendation of “Hold” from the eight research firms that are presently covering the firm, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $2.20.

  • [By Matthew DiLallo]

    Shares of Northern Oil & Gas, Inc. (NYSEMKT:NOG) are flying high, up 12% as of 10:30 a.m. EDT, after the company reported better-than-expected first-quarter results.

  • [By Ezra Schwarzbaum]

    SunTrust analyst Neal Dingmann upgraded shares of Northern Oil & Gas, Inc. (NYSE: NOG) from Hold to Buy and increased his price target from $2 to $4.

Sunday, May 27, 2018

Somewhat Favorable Press Coverage Somewhat Unlikely to Affect CalAmp (CAMP) Stock Price

Media coverage about CalAmp (NASDAQ:CAMP) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. CalAmp earned a news impact score of 0.12 on Accern’s scale. Accern also assigned news coverage about the Wireless communications provider an impact score of 45.2747110123202 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the media stories that may have impacted Accern’s rankings:

Get CalAmp alerts: Comparing CalAmp (CAMP) & Gilat Satellite Networks (GILT) (americanbankingnews.com) Tracking the Consensus EPS For CalAmp Corp. (NASDAQ:CAMP) (derbynewsjournal.com) When to Buy Opportunity? CalAmp Corp. (CAMP) (nysestocks.review) CalAmp Corp. (CAMP) Expected to Post Quarterly Sales of $92.86 Million (americanbankingnews.com) Global GPS Tracking Devices Market Analysis 2018-2023: Calamp, Xirgo Tech., Verizon Wireless, Laipac Tech., Sierra … (brooksinbeta.com)

CAMP opened at $21.31 on Friday. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.89 and a quick ratio of 2.51. CalAmp has a 12 month low of $17.52 and a 12 month high of $25.45. The firm has a market capitalization of $762.05 million, a P/E ratio of 23.16, a PEG ratio of 1.38 and a beta of 1.75.

CalAmp (NASDAQ:CAMP) last announced its earnings results on Thursday, April 26th. The Wireless communications provider reported $0.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.29 by $0.01. The firm had revenue of $94.40 million during the quarter, compared to analyst estimates of $93.57 million. CalAmp had a net margin of 4.54% and a return on equity of 18.54%. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.28 EPS. sell-side analysts forecast that CalAmp will post 1.03 earnings per share for the current fiscal year.

CAMP has been the subject of a number of recent analyst reports. Roth Capital set a $28.00 price objective on shares of CalAmp and gave the company a “buy” rating in a research report on Sunday, May 20th. Zacks Investment Research upgraded shares of CalAmp from a “sell” rating to a “hold” rating in a research report on Thursday, May 10th. ValuEngine upgraded shares of CalAmp from a “hold” rating to a “buy” rating in a research report on Tuesday, May 8th. William Blair restated a “market perform” rating on shares of CalAmp in a research report on Friday, April 27th. Finally, TheStreet cut shares of CalAmp from a “b” rating to a “c+” rating in a research report on Thursday, April 26th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. CalAmp has an average rating of “Buy” and a consensus target price of $26.75.

In related news, CEO Michael J. Burdiek sold 12,500 shares of the company’s stock in a transaction on Tuesday, May 1st. The shares were sold at an average price of $19.58, for a total value of $244,750.00. Following the completion of the transaction, the chief executive officer now directly owns 495,934 shares of the company’s stock, valued at approximately $9,710,387.72. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last ninety days, insiders sold 37,500 shares of company stock valued at $817,500. Company insiders own 5.30% of the company’s stock.

About CalAmp

CalAmp Corp. provides Internet of Things (IoT) enablement solutions for various mobile and fixed applications worldwide. The company provides solutions for mobile resource management and applications for the IoT market, which enable customers in the transportation, government, construction, automotive, and energy markets to optimize their operations by collecting, monitoring, and reporting business-critical data and desired intelligence from remote and mobile assets.

Insider Buying and Selling by Quarter for CalAmp (NASDAQ:CAMP)